Aethlon Medical Inc (AEMD)

$0.35

-0.03

(-8.52%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.34
    $0.40
    $0.35
    downward going graph

    2.86%

    Downside

    Day's Volatility :14.98%

    Upside

    12.48%

    downward going graph
  • $0.24
    $2.93
    $0.35
    downward going graph

    32.14%

    Downside

    52 Weeks Volatility :91.89%

    Upside

    88.05%

    downward going graph

Returns

PeriodAethlon Medical IncIndex (Russel 2000)
3 Months
-40.66%
0.0%
6 Months
-79.55%
0.0%
1 Year
-87.12%
0.0%
3 Years
-99.06%
-22.3%

Highlights

Market Capitalization
5.3M
Book Value
$0.63
Earnings Per Share (EPS)
-3.85
PEG Ratio
0.0
Wall Street Target Price
3.86
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-50.46%
Return On Equity TTM
-105.38%
Revenue TTM
574.2K
Revenue Per Share TTM
0.24
Quarterly Revenue Growth YOY
4278.2%
Gross Profit TTM
574.2K
EBITDA
-10.6M
Diluted Eps TTM
-3.85
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.43
EPS Estimate Next Year
-3.51
EPS Estimate Current Quarter
-0.31
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Aethlon Medical Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
00
Hold
2
2
3
Sell
00
00
3

Analyst Forecast

What analysts predicted

Upside of 1002.86%

Current $0.35
Target $3.86

Technicals Summary

Sell

Neutral

Buy

Aethlon Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aethlon Medical Inc
Aethlon Medical Inc
18.67%
-79.55%
-87.12%
-99.06%
-99.2%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aethlon Medical Inc
Aethlon Medical Inc
NA
NA
0.0
-5.43
-1.05
-0.5
NA
0.63
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aethlon Medical Inc
Aethlon Medical Inc
Buy
$5.3M
-99.2%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Aethlon Medical Inc

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 138.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 180.0%

Institutional Holdings

  • TWO SIGMA SECURITIES, LLC

    0.25%

  • Vanguard Group Inc

    0.15%

  • Geode Capital Management, LLC

    0.15%

  • Baader Bank INC

    0.10%

  • BlackRock Inc

    0.05%

  • Group One Trading, LP

    0.01%

Company Information

the aethlon medical (nasdaq:aemd) mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. our aethlon adapt™ platform provides the technology foundation for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. the aethlon adapt™ product pipeline includes the hemopurifier®, a first-in-class medical device with broad-spectrum capabilities against exosomes that contribute to the progression of cancer and infectious viral pathogens such as hiv and hepatitis c.

Organization
Aethlon Medical Inc
Employees
14
CEO
Mr. James B. Frakes M.B.A.
Industry
Health Technology

Discover More

FAQs